Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Therapeutic efficacy of dose-reduced adjuvant chemotherapy with S-1 in patients with pancreatic cancer: a retrospective study

Fig. 2

Relapse free survival (RFS) of patients according to the total dose ratio (TDI) of adjuvant chemotherapy (AC). The high-TDI group shows significantly better RFS than the low-TDI group and AC(-) group (median, 30 months vs. 8 months, P < 0.001) and AC (-) group (median, 16 months, vs. high-TDI, P = 0.046). There are no significant difference between low-TDI group and AC(-)group (P = 0.166)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us